Heart Tronics, Inc. (HRTT) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerHeart Tronics, Inc. (HRTT) trades at $0.0007. Heart Tronics, Inc. is a medical device company focused on developing and marketing devices for monitoring and measuring physiological signals. Sector: Healthcare.
Price as of · Last analyzed: Mar 16, 2026Analyst Coverage for HRTT: HRTT does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Heart Tronics, Inc. (HRTT) Healthcare & Pipeline Overview
Heart Tronics, Inc. is a medical device company specializing in the research, development, and marketing of devices for physiological signal monitoring in the United States. Their product portfolio includes the Fidelity 100 Monitor System and several devices in development, positioning them in the competitive medical devices market.
What Is the Investment Thesis for HRTT?
Heart Tronics, Inc. operates in the medical device sector, focusing on cardiac monitoring solutions. The company's potential lies in the successful development and commercialization of its pipeline products, such as the Fidelity 350 Holter Monitor and Fidelity 200 Event Recording System. However, the company faces challenges common to small medical device companies, including regulatory hurdles, competition, and the need for significant capital investment to bring products to market. With a market capitalization of $0.00B and a negative P/E ratio, the company's financial performance and future prospects are highly dependent on its ability to secure funding and achieve regulatory approvals. The negative beta of -2.08 suggests an inverse correlation with the market, which could be a factor for investors to consider.
Based on FMP financials and quantitative analysis
HRTT Key Highlights
Heart Tronics, Inc. operates in the medical device industry, focusing on cardiac monitoring solutions.
- The company's flagship product is the Fidelity 100 Monitor System, an integrated ECG signal monitoring system.
- Several products are in the development stage, including the Fidelity 350 Holter Monitor and Fidelity 200 Event Recording System.
- The company has a market capitalization of $0.00B.
- Heart Tronics has a negative P/E ratio, reflecting its current financial performance.
Who Are HRTT's Competitors?
HRTT is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| BJDX Bluejay Diagnostics, Inc. | $0.76 | -9.01% | 30 5-pillar | |
| NVNO enVVeno Medical Corporation | $8.01 | -1.11% | $5.63M | 30 5-pillar |
| BDMD Baird Medical Investment Holdings Limited | $0.74 | -1.09% | $31.4M | — |
| SNWV SANUWAVE Health, Inc. | $4.70 | -2.49% | $41.5M | 36 5-pillar |
| SRTS Sensus Healthcare, Inc. | $2.92 | -2.01% | $48.1M | 31 5-pillar |
| HYPD Hyperion DeFi, Inc. | $3.89 | +4.29% | $56.5M | 36 5-pillar |
| LNSR LENSAR, Inc. | $6.67 | -1.19% | $81.9M | 45 5-pillar |
| APYX Apyx Medical Corporation | $2.60 | +1.96% | $107M | 33 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are HRTT's Key Strengths?
Proprietary technology in physiological signal acquisition.
- Integrated system approach with the Fidelity 100 Monitor System.
- Pipeline of products in development targeting various cardiac monitoring needs.
- Long-standing presence in the medical device industry.
What Are HRTT's Weaknesses?
Limited financial resources and market capitalization.
- Dependence on successful development and commercialization of pipeline products.
- Competition from larger, more established medical device companies.
- OTC market listing indicates higher risk and lower liquidity.
What Are the Key Risks for HRTT?
Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Failure to secure regulatory approvals for pipeline products.
- Competition from larger, more established medical device companies.
- Limited financial resources and difficulty in raising capital.
- Technological obsolescence and the emergence of competing technologies.
- Dependence on successful commercialization of a limited number of products.
What Threats Does HRTT Face?
- Stringent regulatory requirements and approval processes.
- Technological obsolescence and the emergence of competing technologies.
- Economic downturns and reduced healthcare spending.
- Product liability and safety concerns.
What Are HRTT's Competitive Advantages?
- Proprietary Physiological Signal Acquisition Technology: Heart Tronics possesses unique technology for acquiring and amplifying physiological signals, potentially providing a competitive edge in signal clarity and accuracy.
- Integrated System Approach: The Fidelity 100 Monitor System offers an integrated solution for ECG monitoring, combining hardware and software for comprehensive data collection and analysis.
- Pipeline of Development Products: The company has several products in the development stage, offering the potential for future revenue streams and market expansion.
- Established Brand Name: Heart Tronics, formerly Signalife, has been in operation since 1987, establishing a brand presence and reputation within the medical device industry.
What Does HRTT Do?
Heart Tronics, Inc., formerly known as Signalife, Inc., was incorporated in 1987 and rebranded in November 2008. Headquartered in Studio City, California, the company focuses on the research, development, and marketing of medical devices designed to monitor and measure physiological signals. These devices aim to aid in the early detection and management of diseases affecting individual health. The company's flagship product, the Fidelity 100 Monitor System, is an integrated system that collects, processes, and amplifies electrocardiogram (ECG) signals via a set of electrodes wirelessly transmitting data to a laptop. Heart Tronics also has several products in the development stage, including the Fidelity 350 Holter Monitor, an ambulatory device for detecting arrhythmia and transient heart disease, and the Fidelity 200 Event Recording System/Heart Tempo Card, a non-prescription heart monitoring device. Additional products include the Cardiac Vest and the Fidelity 400 Intracardiac Monitor, which applies proprietary signal acquisition technology to read intracardiac signals. Heart Tronics aims to provide innovative solutions for cardiac monitoring and diagnostics.
What Products and Services Does HRTT Offer?
- Researches and develops medical devices.
- Markets medical devices in the United States.
- Focuses on devices that monitor and measure physiological signals.
- Offers the Fidelity 100 Monitor System for ECG signal monitoring.
- Develops ambulatory Holter monitors for arrhythmia and heart disease detection.
- Creates non-prescription heart monitoring devices for early detection.
How Does HRTT Make Money?
- Develops and sells medical devices for cardiac monitoring.
- Generates revenue through the sale of the Fidelity 100 Monitor System.
- Aims to generate future revenue from the sale of devices currently in development.
- Potentially generates revenue through partnerships and distribution agreements.
What Industry Does HRTT Operate In?
Heart Tronics, Inc. operates within the medical device industry, a sector characterized by continuous innovation and stringent regulatory requirements. The market for cardiac monitoring devices is driven by the increasing prevalence of cardiovascular diseases and the growing demand for early and accurate diagnostics. Competition is intense, with established players and emerging companies vying for market share. Heart Tronics' success depends on its ability to differentiate its products, navigate regulatory pathways, and secure funding for research and development. The industry is also influenced by technological advancements, such as wireless connectivity and remote monitoring, which are shaping the future of cardiac care.
Who Are HRTT's Key Customers?
- Hospitals and clinics that use cardiac monitoring devices.
- Physicians who need tools for diagnosing and monitoring heart conditions.
- Patients who require ECG monitoring and cardiac health assessments.
- Individuals seeking non-prescription heart monitoring devices for early detection.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Company Profile
Heart Tronics, Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Studio City, US. HRTT has traded publicly since 1999.
Financial Health
Heart Tronics, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
HRTT Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
HRTT Latest News
No recent news available for HRTT.
HRTT Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for HRTT.
Price Targets
Wall Street price target analysis for HRTT.
HRTT MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for HRTT; grades run from A+ (80-100) to F (below 30).
Leadership: Budimir S. Drakulic
CEO
Budimir S. Drakulic serves as the CEO of Heart Tronics, Inc. His background includes experience in managing small teams and overseeing the operations of the company. As CEO, he is responsible for the overall strategic direction and management of Heart Tronics, including research and development, marketing, and financial performance. He manages a team of 13 employees.
Track Record: Under Budimir S. Drakulic's leadership, Heart Tronics has focused on the development and marketing of its medical devices, including the Fidelity 100 Monitor System. Key milestones include the continued development of the Fidelity 350 Holter Monitor and Fidelity 200 Event Recording System. The company's progress is contingent on securing regulatory approvals and achieving commercial success with its product pipeline. Specific financial achievements and strategic decisions are not detailed in the provided information.
HRTT OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Heart Tronics, Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQB or OTCQX. Companies in this tier may have limited or no financial disclosure, making it difficult for investors to assess their financial health and operational performance. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other companies face fewer regulatory requirements, resulting in increased risk and potential for fraud or manipulation.
- OTC Tier: OTC Other
- Limited or no financial disclosure, making it difficult to assess the company's financial health.
- Low trading volume and wide bid-ask spreads, leading to potential price volatility.
- Higher risk of fraud or manipulation due to less stringent regulatory oversight.
- Potential for delisting or suspension of trading due to non-compliance with OTC market requirements.
- Limited access to capital and funding opportunities compared to companies listed on major exchanges.
- Verify the company's legal status and registration with relevant authorities.
- Attempt to obtain and review any available financial statements or disclosures.
- Assess the company's management team and their experience in the medical device industry.
- Research the company's products and their potential market demand.
- Evaluate the company's competitive landscape and its ability to differentiate itself.
- Understand the risks associated with investing in OTC Other stocks.
- Consult with a financial advisor before making any investment decisions.
- Company has been in operation since 1987, indicating a long-standing presence in the industry.
- Focus on research and development of medical devices, suggesting a commitment to innovation.
- Development of the Fidelity 100 Monitor System and other products, demonstrating tangible progress.
- CEO Budimir S. Drakulic is managing 13 employees, suggesting a functional organizational structure.
- Company is headquartered in Studio City, California, a known business hub.
HRTT Healthcare Stock FAQ
How does Heart Tronics, Inc. navigate regulatory approval processes?
As a medical device company, Heart Tronics, Inc. must navigate stringent regulatory approval processes to bring its products to market. In the United States, this primarily involves the Food and Drug Administration (FDA).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Information is limited to the provided source data.
- OTC market stocks carry higher risk than exchange-listed stocks.